Innovative Pricing Models in the EU: Making Medicines Affordable for All
Debi Jones, Editorial Team, Pharma Focus Europe
In this article, we discuss new approaches to drug pricing in the EU: value based pricing, risk sharing, subscription and differential pricing. These strategies are to achieve cost reduction for medicines now and the future to be more affordable, sustained and accessible, and to advance pharmaceutical innovation. Future trends, opportunities and threats such as regulation and structuring of data are also examined.
Pricing policies are important determinants in delivering sufficiently cheap medicines in all the 27 member nations of the EU. High costs of meeting the required medical care together with arising independent differentiated technological improvements have rendered exhausted pricing structures as uncompetitive tools for fairness. New mechanisms of pricing have been introduced in an effort to reconcile the issues of cost sensitivity, innovation, and sustainability objectives including value-based pricing, risk share deals and subscriptions. This article reviews these strategies explaining the effect they have on the cost of healthcare and the regulatory and operational concerns associated with them.
Introduction:
It is a well-established fact that the supply of cheap medicines cannot be the hallmark of an efficient health delivery system. Nevertheless, controlling the high prices of innovative products in the health care sector of the EU has emerged as a burning, more so, considering the increasing demand for innovative drugs, which puts pressure on the public healthcare budget. As a result, there has been the rise of new and efficient approaches for negotiating prices for the needed medicines while ensuring economic feasibility for the providers. All these new approaches are not only about the benefits for the patients but also for organization that produce chemical products to cover their costs spend on research and development (R & D).
The Need for Innovation in Drug Pricing
Extend models of pricing come with certain problems in the light of escalating drug prices. These methods often have embedded messages to the effect that all patients and countries should be charged a similar price for drugs; this is a concept that has become dated due to high costs needed to treat conditions such as gene therapy, which may cost US$2,000,000 for every patient. Additionally, most of the times, expensive prices of the drugs make it difficult for some patients to get the drugs that they need. This is in addition to the challenges of budget when it comes to implementing high ended healthcare services for the generality of the populace. This situation requires new ways of setting the price for drugs that will ensure increased access and affordability while at the same time being sustainable.
Emerging Pressures in the EU
The EU is in a way or the other challenged in regulating drug prices.
The fiscal condition of the member states differs from one country to the other; implying that what one nation can afford is different from the next nation. There is also an increasing need for balanced access to medicines, and at the same time, innovation. The EU also experience regulatory forces which demand that all the drugs in the market must have met strict safety and efficacy requirements. Such factors explain the necessity of the novel pricing models that can meet the requirements of the different EU member state besides the promotion of new and effective treatments.
Innovative Pricing Models: An Overview
In tackling the problems introduced by conventional pricing schemes, the EU has started testing revolutionary pricing options. These models for pricing should strike a balance between costs and development of innovative drugs on one’s side, and the ability of patients to afford these costly drugs on the other. The following pricing models are also emerging in the EU market.
Value-Based Pricing (VBP)
Value-based pricing is a system of pricing of a particular product within which pricing depends on the client’s value of the given good or service, instead of the cost of creating the product and the number of people who would be willing to buy the given product. This approach is applied to strive to make drug cost equal to the actual value and include the ability to improve patients’ quality of life as well as reduce the rates of hospitalization. The disproportionate effect would mean that the high impact drugs that improve the quality of patients will be costly under this model. While identifying ‘value’, one encounters certain issues that might warrant well developed systems for collecting data. Nevertheless, VBP promotes the emergence of higher quality treatments and guarantees price more relevant to the value of a drug for patients and society.
Risk-Sharing Agreements (RSAs)
Manufacturers and product-approver share potential risks associated with the performance of a drug through risk-sharing agreements. What the health care providers receive in return for their activities is compensated by focusing on contracts that are associated with certain results such as the number of patients recovering, or the rate at which diseases are contained. In case the consumers do not get the anticipated outcomes of the medications, manufacturers may provide customer rebates. This decrease in liability minimizes the potential cost for the delivering of healthcare services and it makes sure that the pharmaceuticals are trained to continue being responsible for the effectiveness of their products. But RSAs can be somewhat difficult to execute because of the significant amount of monitoring and information exchange necessary to determine the efficacy of drugs.
Subscription Models (“Netflix Model”)
The subscription model also known as Netflix model is a model where health care systems or government pays a fixed annual fee in exchange for as many drugs as they want during the period of the subscription. This model is commonly used with costly drugs for chronic diseases, for example, hepatitis C, and it presupposes subscription charges with manufacturers that will help healthcare systems estimate their drug costs. The main benefit of this model is increased budget control and patients’ access to needed medicines without extra costs per vial. However, very careful negotiation is needed to avoid situation where governments are pressured into overpaying for a product and there for this model may not work well for treatment that have probabilities that are hard to predict.
Differential Pricing
Differential pricing put in practice means that the drug costs significantly differ depending on the ability of each country to purchase the expensive medication. Developed countries are charged more for the drugs, while the poor nations get the drugs at an almost Throw Away Price. This model seeks to ensure that everyone especially the country with a low income will have an access to the necessary drugs. While helping poorer nations to bear less costs, differential pricing helps guarantee that EU member states need not spare resources on expensive treatments. But it also threatens parallel trade were products, including cheaper drugs manufactured in low-income countries, are imported and sold in higher income zones at a higher price.
Examples of Successful Implementation in the EU
A number of EU countries have already adopted other models involving innovative price approaches with desirable results. In Italy, managed entry agreements have been very useful in managing the high costs associated with cancer and other rare diseases. This enable manufacturer to recover the cost of the drugs that have not met the required performance standards. A UK’s Cancer Drugs Fund outlines a strategic which includes value-based pricing and risk-sharing agreements to ensure that expensive cancer medication is made available while its contribution is determined. Spain has implemented successful subscription based model, which makes expensive treatments like hepatitis C treatment accessible to everyone and brought improved results to public health.
Challenges in Adopting Innovative Pricing Models
However, the use of innovative prices poses a challenge when it comes to the implementation of the models in the EU. Admittedly, the variation of organizational structures of healthcare and presence of different laws and regulations in member countries does not allow for standardization of pricing strategies. Besides, most of these models impose on real-world data, which is a disadvantage when it comes to data privacy and sharing. Deciding reasonable prices for purchasing the drugs from manufacturers and governments may also be a lengthy and a very sensitive exercise. Furthermore, there is the problem of how to make these models operate financially sustaining in the long run, but at the same time not hampering innovation.
Future Directions
In order to introduce the innovative pricing models into full and efficient operation, the EU needs to act in synergy. Member states should agree in order to bargain on prices and to exchange information, this, in order to contribute to the formation of a collective health care system. Evaluation of the performance and value of drugs will require investment in analytics including data infrastructure both in depth and breadth of which will include real world evidence. It also enhances the chances of implementing the diverse form of pricing models through developed standardized regulatory system in addressing the patient’s interest. Governments and manufacturers in partnership with healthcare systems must develop strategies that will make it possible for all patients to access the newly developed pricing models in the markets.
Conclusion
New approaches to food pricing are a major step in increasing the availability of medicines for people within the EU. If the EU has to preserve the health system sustainable while stimulating the growth of novelties, techniques like value-based price setting, risk-sharing, and subscriptions schemes must be implemented. However, implementing measures to counter the issues of regulation complexity, data management, and negotiation will be a critical success factor of these models. The cooperative action and strategic investments today will enable the EU become a model of the equitable and efficient system of healthcare in the future.
Debi Jones, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Debi contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
